#254 Global Rank Marché Ouvert

Robert Duggan

Santé & Biotech. Pharmaceuticals.

Fortune Nette (Est.)

$12.7 B
+$229 (+0.00%) Aujourd'hui
Portefeuille : AbbVie Inc. ▲ High Growth Akeso Inc ▲ High Growth Alphabet ▲ High Growth Boston Scientific ▲ High Growth
Robert Duggan

Photo: Press Agency / 2026

Profil Financier

Robert Duggan occupe actuellement le rang #254 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $12.7 B (+$229 sur 24h).

In 2020, Robert Duggan invested $63 million in Nasdaq-listed Summit Therapeutics and became its Co-CEO, leading the biotech in developing targeted oncology therapies for difficult diagnoses.

Pharmacyclics' cancer drug Imbruvica made Duggan a billionaire in 2013 and paved the way for the company's $21 billion sale to AbbVie in 2015.

Duggan, whose son died from brain cancer, became passionate about Pharmacyclic's cancer fighting drugs and first invested in 2004.

His enthusiasm for investing began four decades earlier in a corporate finance class he took at the University of California at Santa Barbara.

He married Summit co-CEO Maky Zanganeh, who is also a billionaire, in 2024.

Duggan also sits on the board of Pulse Biosciences, of which he is the largest individual shareholder.

Duggan is a big donor to the Church of Scientology, of which he is a member; he says he's given the church nearly $360 million over his lifetime.

Duggan enjoys surfing in his spare time.

Historique de Fortune (12 Mois)

1A 5A Max
Jan 25 Juin 25 Déc 25 Auj.

Répartition des Actifs

Actif / Société Parts Détenues Valeur Est. Tendance
AbbVie Inc. (ABBV) 100 parts $26,282 High Growth
Akeso Inc (9926-HK) 2.9M parts $39 M High Growth
Alphabet (GOOGL) 5.0K parts $2 M High Growth
Boston Scientific (BSX) 100 parts $4,260 High Growth
Edwards Lifesciences (EW) 100 parts $8,515 High Growth